Aviv Regev re­cruits a ‘pur­ple uni­corn’ for the top post in the com­pu­ta­tion­al pil­lar she’s build­ing at Genen­tech

Two years af­ter Aviv Regev left her sci­en­tif­ic abode at the Broad and jour­neyed west to take over as the new head of re­search and ear­ly de­vel­op­ment at Genen­tech, she’s tak­ing an­oth­er big step in us­ing com­pu­ta­tion­al bi­ol­o­gy to re­make ear­ly drug re­search at the sto­ried Roche biotech di­vi­sion in South San Fran­cis­co.

Regev took some time yes­ter­day to walk me through a key hire she’s clear­ly pumped about. This sum­mer, John Mar­i­oni will leave his mul­ti­ple pres­tige posts in­volv­ing com­pu­ta­tion­al bi­ol­o­gy in Cam­bridge, UK — se­nior sci­en­tist at the Eu­ro­pean Bioin­for­mat­ics In­sti­tute, a po­si­tion with the Sanger In­sti­tute and pro­fes­sor at Cam­bridge Uni­ver­si­ty — and bring his ex­per­tise in an­a­lyz­ing sin­gle cell ge­nomics to the Bay Area drug de­vel­op­er.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE